GlassScriptPhysician profile
William D Clever
NPI 1982608758
$10,538.04
in general payments reported to CMS, 2019-2025
43 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,553 · 2023: $2,040 · 2024: $2,869 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,702.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,909.05 | 2021-2025 | |
| Novo Nordisk INC | $1,273.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $692.25 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $610.07 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ucb, INC. | $578.05 | 2022-2025 | Nayzilam, Briviact |
| Lilly USA, LLC | $538.08 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $433.74 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $432.57 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $368.08 | 2022-2025 | Ingrezza, Ongentys |
| Amgen INC. | $354.55 | 2021-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $353.96 | 2021-2025 | |
| Axsome Therapeutics, INC. | $290.18 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.19 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $232.43 | 2025 | Rexulti, Abilify Maintena |
| Xeris Pharmaceuticals, INC. | $193.40 | 2023-2025 | Gvoke Hypopen |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $178.97 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $167.27 | 2021-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.80 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.95 | 2021-2025 | Jardiance, Synjardy |
| Ardelyx, INC. | $122.14 | 2024-2025 | Ibsrela |
| Intra-Sana Laboratories | $107.36 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $102.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $101.03 | 2021-2023 | Breztri |
| Dexcom, INC. | $97.38 | 2021-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $93.62 | 2021-2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $88.63 | 2022 | |
| Intuitive Surgical, INC. | $82.47 | 2025 | |
| Pfizer INC. | $68.47 | 2021-2023 | |
| Astellas Pharma US INC | $64.01 | 2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $63.60 | 2024-2025 | Eliquis, Cobenfy |
| Exact Sciences Corporation | $59.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $49.17 | 2021 | |
| Amarin Pharma, INC. | $37.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.46 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $30.95 | 2023 | Austedo Xr, Uzedy |
| Tandem Diabetes Care, INC. | $30.88 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Biogen, INC. | $20.65 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.51 | 2022 | |
| Radius Health, INC. | $16.69 | 2024 | Tymlos |
| Alkermes, INC. | $15.20 | 2023 | Lybalvi |
| Acadia Pharmaceuticals INC | $14.53 | 2022 | |
| Merck Sharp & Dohme LLC | $14.30 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Clever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.